| Gender Preference | None |
| Age Group | 18 - 80 years |
| Research Start Date | April 11, 2012 |
| Research End Date | September 1, 2014 |
| Principal Investigator | Sif Hansdottir, MD |
| Description | Chest -2 Long-term Extension, Multicentre, Multi-international Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg, 1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Patients who have completed 16 weeks of treatment in the double blind trial CHEST 1
Riociguat (BAY63-2521)
BAY63-2521 - 1 mg tid - 2,5 mg tid orally until end of study
for more information go to www.clinicaltrials.gov Identifier NCT00910429 |
| Contact Info | Pulmonary Hypertension Program
Cynthia Larew RN 319-356-1028 pager # 2123
cynthia-larew@uiowa.edu
|
| Keywords | span itemProp='description'>Chest -2 Long-term Extension ; Chronic Thromboembolic Pulmonary Hypertension ; CTEPH ; Heart ; High blood pressure in lungs ; PH ; pulmonary hypertension ; |